Clinical Research Directory

Inclusion Criteria: * Adults aged 18 and above * DSM-5 Cannabis Use Disorder diagnosis of at least moderate severity (4+ DSM-5 symptoms) * 4 or more days of cannabis use per week * Treatment seeking * A Body Mass Index (BMI) ≥ 22 Exclusion Criteria: * Meet DSM-5 criteria for Cluster A or B personality disorders and/or unstable current bipolar disorder, schizophrenia, or psychotic disorder * Comorbid severe DSM-5 Major Depressive Disorder * Present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study, as determined by the study physician and Columbia Suicide Severity Rating Scale * Any other mental health condition deemed incompatible by the study team * Meet DSM-5 criteria for alcohol or substance use disorder for any substance other than cannabis or tobacco in the past 6 months * Positive urine drug screen for any substance except cannabis * Concurrent addiction-focused psychotherapy in the past 6 months * Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months * A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 * Current unstable medical condition * A lifetime diagnosis of Diabetes * Females who are pregnant/nursing, or individuals in reproductive age who do not consent to using birth control during the study * Concomitant treatment with: other GLP-1 agonists, Contrave, bupropion, naltrexone, acamprosate within the past year. No lifetime treatment with tirzepatide. * Significant literacy, visual, or hearing problems * Co-enrollment in a clinical drug trial